Pilot Study for Optimization of Immuno-PET Pretargeted With Anti-CEA Bispecific Antibody X Anti-HSG TF2 and the Peptide IMP-288 Radiolabeled With Gallium-68 -Pharmacokinetic and Imaging for Patients With a Recurrence of HER2 Negative Breast Carcinoma Expressing CEA

Trial Profile

Pilot Study for Optimization of Immuno-PET Pretargeted With Anti-CEA Bispecific Antibody X Anti-HSG TF2 and the Peptide IMP-288 Radiolabeled With Gallium-68 -Pharmacokinetic and Imaging for Patients With a Recurrence of HER2 Negative Breast Carcinoma Expressing CEA

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 23 Jan 2017

At a glance

  • Drugs Gallium-68-IMP-288 (Primary) ; TF 2 (Primary)
  • Indications Cancer metastases
  • Focus Diagnostic use
  • Acronyms iTEPsein
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 17 Jan 2017 Planned End Date changed from 1 Dec 2016 to 1 Apr 2017.
    • 17 Jan 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Jan 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top